Cyclin D1 predicts the prognosis of advanced serous ovarian cancer

Hashimoto,Tomoko; Yanaihara,Nozomu; Okamoto,Aikou; Nikaido,Takashi; Saito,Misato; Takakura,Satoshi; Yasuda,Makoto; Sasaki,Hiroshi; Ochiai,Kazunori; Tanaka,Tadao

doi:10.3892/etm.2011.194

Cyclin D1 predicts the prognosis of advanced serous ovarian cancer

Authors:
- Tomoko Hashimoto
- Nozomu Yanaihara
- Aikou Okamoto
- Takashi Nikaido
- Misato Saito
- Satoshi Takakura
- Makoto Yasuda
- Hiroshi Sasaki
- Kazunori Ochiai
- Tadao Tanaka
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo 105-8461, Japan, Department of Pathology, Kosei General Hospital, Tokyo, Japan, Department of Obstetrics and Gynecology, Jikei Kashiwa Hospital, Chiba, Japan
Published online on: January 18, 2011 https://doi.org/10.3892/etm.2011.194
Pages: 213-219

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We previously reported that cyclin E (CCNE1) amplification is strongly associated with resistance to treatment in serous ovarian cancer by high-resolution oligonucleotide copy number analysis. Dysregulation of cell cycle control has been implicated as the key event in human oncogenesis, and aberrant expression of G1-S phase-related genes in particular has been reported in epithelial ovarian cancer (EOC). Nevertheless, there are conflicting results concerning the prognostic values of these abnormalities in EOC. This study focused on advanced serous EOC cases and investigated the association between the expression of G1-S phase-regulatory proteins and clinicopathological parameters. The utility of these proteins as prognostic factors was assessed, and whether these targets reflect chemoresistance of advanced serous EOC was investigated. A total of 66 patients treated by primary surgery were evaluated in this study. Immunohistochemical analysis for cyclin D1, pRb, p16, p53, p27Kip1, p21Waf1/Cip1 and cyclin E was performed on formalin-fixed tissue sections collected from primary surgical specimens. The correlations between the expression of these proteins and the clinicopathological parameters, including progression-free survival (PFS), overall survival (OS) and chemosensitivity, were examined. Upon univariate analysis, overexpression of cyclin D1 was positively correlated with reduced PFS (p=0.00062) and OS (p=0.00037). Reduced expression of p27Kip1 was associated with shorter OS (p=0.064). Upon multivariate analysis, overexpression of cyclin D1 (p=0.0019), reduced expression of p27Kip1 (p=0.042) and residual tumor volume (p=0.0092) were identified as independent predictors of OS. Overexpression of cyclin D1 (p=0.011) as well as residual tumor volume (p=0.006) were significantly associated with first-line chemosensitivity. In advanced serous EOC, overexpression of cyclin D1 contributed largely to poor prognosis, and this may have been in part mediated by chemoresistance. Cyclin D1 is a possible target for overcoming the refractory nature of advanced serous EOC.

View Figures

View References

1.	Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, Noda K, Sugiyama T and Ochiai K; Japanese Gynecologic Oncology Group: Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer. 20:240–247. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T and Kaku T: Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol. 113:331–334. 2009. View Article : Google Scholar : PubMed/NCBI
3.	Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K and Noda K; Japanese Gynecologic Oncology Group: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 374:1331–1338. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Barbieri F, Lorenzi P, Ragni N, Schettini G, Bruzzo C, Pedullà F and Alama A: Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Oncology. 66:310–315. 2004. View Article : Google Scholar : PubMed/NCBI
6.	NIH Consensus Conference: Ovarian cancer. Screening, treatment, and follow-up. JAMA. 273:491–497. 1995. View Article : Google Scholar
7.	Terauchi F, Nishi H, Moritake T, et al: Prognostic factor on optimal debulking surgery by maximum effort for stage IIIC epithelial ovarian cancer. J Obstet Gynaecol Res. 35:315–319. 2009. View Article : Google Scholar : PubMed/NCBI
8.	Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I and Pfisterer J: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 115:1234–1244. 2009.
9.	Chi DS, Eisenhauer EL, Zivanovic O, et al: Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 114:26–31. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, Chiew YE, Traficante N, Fereday S, Johnson D, Fox S, Sellers W, Urashima M, Salvesen HB, Meyerson M and Bowtell D; AOCS Study Group: Integrated copy number and expression analysis of chemoresistant ovarian carcinomas. Clin Cancer Res. 15:1417–1427. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Bali A, O’Brien PM, Edwards LS, Sutherland RL, Hacker NF and Henshall SM: Cyclin D1, p53, and p21^Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res. 10:5168–5177. 2004.
12.	Psyrri A, Bamias A, Yu Z, et al: Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res. 11:8384–8390. 2005. View Article : Google Scholar
13.	Khouja MH, Baekelandt M, Nesland JM and Holm R: The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol. 26:418–425. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Milde-Langosch K and Riethdorf S: Role of cell-cycle regulatory proteins in gynecological cancer. J Cell Physiol. 196:224–244. 2003. View Article : Google Scholar : PubMed/NCBI
15.	Kommoss S, du Bois A, Ridder R, Trunk MJ, Schmidt D, Pfisterer J and Kommoss F; AGO-OVAR: Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br J Cancer. 96:306–313. 2007.
16.	Sherr CJ: G1 phase progression: cycling on cue. Cell. 79:551–555. 1994. View Article : Google Scholar : PubMed/NCBI
17.	Dhar KK, Branigan K, Parkes J, et al: Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells. Br J Cancer. 81:1174–1181. 1999. View Article : Google Scholar : PubMed/NCBI
18.	Worsley SD, Ponder BA and Davies BR: Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol. 64:189–195. 1997. View Article : Google Scholar : PubMed/NCBI
19.	Barbieri F, Cagnoli M, Ragni N, Foglia G, Bruzzo C, Pedullà F and Alama A: Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res. 5:1837–1842. 1999.PubMed/NCBI
20.	Masciullo V, Scambia G, Marone M, et al: Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas. Int J Cancer. 74:390–395. 1997. View Article : Google Scholar : PubMed/NCBI
21.	Diebold J, Mösinger K, Peiro G, et al: 20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence in situ hybridization. J Pathol. 190:564–571. 2000. View Article : Google Scholar : PubMed/NCBI
22.	Jiang Q, Feng MG and Mo YY: Systematic validation of predicted microRNAs for cyclin D1. BMC Cancer. 9:1942009. View Article : Google Scholar : PubMed/NCBI
23.	Zhou X, Zhang Z, Yang X, Chen W and Zhang P: Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell carcinoma cells is associated with increased cisplatin chemosensitivity. Int J Cancer. 124:483–489. 2009. View Article : Google Scholar : PubMed/NCBI
24.	Biliran H Jr, Wang Y, Banerjee S, et al: Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res. 11:6075–6086. 2005. View Article : Google Scholar
25.	Blain SW, Scher HI, Cordon-Cardo C and Koff A: p27 as a target for cancer therapeutics. Cancer Cell. 3:111–115. 2003. View Article : Google Scholar : PubMed/NCBI
26.	Nam EJ and Kim YT: Alteration of cell-cycle regulation in epithelial ovarian cancer. Int J Gynecol Cancer. 18:1169–1182. 2008. View Article : Google Scholar : PubMed/NCBI
27.	Shigemasa K, Shiroyama Y, Sawasaki T, et al: Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas. Int J Oncol. 18:953–958. 2001.PubMed/NCBI